35 results about "Terbutaline" patented technology

The invention relates to a preparation method of high optical purity and high chemical purity levo(-)terbutaline. The method provided by the invention has the advantages of cheap and easily availablebulk drugs, simple operation and short reaction period, is suitable for industrial production, improves the total yield, and at the same time can acquire high optical purity and high chemical purity product. The high optical purity and high chemical purity levo(-)terbutaline provided by the invention is applied to drug efficacy study of resistance to asthma and obstructive pulmonary disease. The result indicates that compared with the commercially available despinners, the levo(-)terbutaline can improve the anti-asthma efficacy manyfold, and proves a new obtains products with high chemicalpurity and optical purity. The anti-asthma and pulmonary obstruction effects of levo-terbutaline with high optical purity and high chemical purity in the present invention were studied. The results show that levoterbutaline in the invention can double the antiasthmatic efficacy compared with racemates sold in the market, and provides a new optimal treatment scheme for asthma related diseases.

The present invention relates to a bambuterol hydrochloride tablet composition, which comprises, by mass, 5-10% of bambuterol hydrochloride, 30-60% of lactose, 10-40% of starch, 10-30% of sodium carboxymethyl starch, 1-3% of talc powder, 0.2-0.8% of magnesium stearate, and 0.2-0.8% of sodium carboxymethyl cellulose. According to the present invention, the plasma half-life is about 17 h after the bambuterol hydrochloride tablet composition is subjected to oral administration, the plasma half-life of the active metabolite terbutaline is about 17 h, the effective action effect of the bambuterol hydrochloride tablet composition can achieve 24 h, the bambuterol hydrochloride tablet composition is only be taken once every night so as to achieve easy administration, the medical values are provided for asthma patients with easy attacking at night or on the morning and aggravation, and the bambuterol hydrochloride tablet composition is an ideal anti-asthmatic drug.

The present invention discloses a novel compound and method for the treatment of inflammatory autoimmune diseases, for example, rheumatoid arthritis, using α-adrenergic antagonists and β-adrenergic agonists in combination. Treatment of animals, namely humans, with an α-adrenergic antagonist, preferably, phentolamine, and a β-adrenergic agonist, preferably terbutaline, in combination can significantly suppress the joint destruction and inflammation due to disease in these animals.

The invention relates to the technical field of preparation and application of chiral high-performance liquid chromatography column materials, and discloses preparation and application of beta-CD-D2 high-performance liquid chromatography chiral column material. A high-performance liquid chromatography chiral column is prepared from beta-CD-D2 and is used for splitting chiral medicine enantiomers. The preparation and the application of the beta-CD-D2 high-performance liquid chromatography chiral column material comprise the following steps: 1, constructing a chiral environment by using beta-CD-D2, bonding the chiral environment with high-performance liquid chromatography silica beads into a fixed phase filler, then preparing the fixed phase filler into a chiral column, and applying the chiral column into high-performance liquid chromatography; 2, finding out an optional formula and an optional condition by using a proper characterization means, and optimizing the method and the condition; 3, establishing a preparation method of a salmeterol single enantiomer by using the prepared beta-CD-D2 chiral column, and splitting a chiral compound by using a cyclodextrins derivative for the first time; and 4, splitting drugs by using the prepared beta-CD-D2 chiral column, and establishing a method for splitting and qualitatively and quantitatively analyzing seven chiral drugs including salmeterol, terbutaline, procaterol, cetirizine, lamivudine, cefuroxime and ceftriaxone.

This invention disclosed new use of R-terbutaline and other R-enantiomer [beta]2-agonists as immune-modulators for treatment of bronchia-lung inflammatory symptoms or inflammatory fibrosis remolding. This invention also disclosed new use of R-terbutaline and R-[beta]2-agonists for reduced adverse effects related to racemic or S-enantiomer [beta]2-agonists including airway hyper responsiveness and airway fibrosis.

The invention discloses an immune-electrochemistry sensor for detecting seven beta-adrenergic receptor agonists, and a manufacture method and application of the immune-electrochemistry sensor. The immune-electrochemistry sensor comprises a substrate glass electrode, and a film layer and a detection layer which sequentially coat the surface of the substrate glass electrode, wherein the material of the detection is a beta-agonist general hapten 4-(4-(2-terttert-butylamino) 1-ethoxy) phenylbutyric acid solution. The method comprises the following steps: firstly dispensing graphene / chitosan dispersion liquid on the surface of the clean substrate glass electrode, drying to form a film formation layer, dispensing the 4-(4-(2-terttert-butylamino) 1-ethoxy) phenylbutyric acid solution on the surface of the film layer, and then drying. The sensor is based on the cross immunoreactions of a beta-agonist broad specificity antibody on various beta-agonists, and can realize the detection of seven beta-agonists including clenbuterol, salbutamol, mabuterol, brombuterol, cimbuterol, tulobuterol and terbutaline.

The invention relates to the field of biotechnology, and discloses an anti-β-receptor agonist cluster-specific monoclonal antibody hybridoma cell line and the monoclonal antibody secreted therefrom. The hybridoma cell line of the present invention is prepared from salbutamol artificial antigen, and the monoclonal antibody secreted by it can simultaneously recognize salbutamol, clenbuterol hydrochloride, terbutaline, bromobuterol and sibuterol and other β-receptor agonists, Has cluster specificity; the immunoaffinity chromatography gel prepared from this is mixed with other β‑receptor agonists, such as ractopamine, as a purification reagent for machine test pretreatment and HPLC‑FLD, LC‑MS / The combination of MS detection technology can efficiently detect various clenbuterol components in pork, pig liver and pig urine samples, with high accuracy and sensitivity.

The invention discloses an electrochemical immunosensor capable of detecting various beta-adrenergic receptor stimulants (short for beta-stimulants). The sensor comprises a base electrode, a graphene / chitosan complex membrane and multi-determinant antigens of beta-stimulants, wherein the graphenee / chitosan complex membrane is modified on the surface of the base electrode, and the multi-determinant antigens of the beta-stimulants are fixed on the surface of the graphene / chitosan complex membrane. The multi-determinant antigens fixed on the surface of the sensor are salbutamol-ractopamine-BSA or salbutamol-ractopamine-OVA. The invention also provides an electrochemical immunodetection method for various beta-stimulant residues. The electrochemical immunosensor can be used for detecting six beta-stimulants including clenbuterol, salbutamol, ractopamine, terbutaline, mabuterol and tulobutezol through carrying out cross immune reaction on the beta-stimulants based on wide-spectrum specific antibodies of the beta-stimulants by taking K3[Fe(CN)6] as a probe.